Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment

Growth Hormone and IGF Research

Volumn 13, Issue 6, 2003, Pages 322-327

  Höybye, Charlotte ^a   Barkeling, Britta ^a   Espelund, Ulrick ^b   Petersson, Maria ^a   Thorén, Marja ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adults; GH treatment; Hyperphagia; Obesity; Peptides; Prader Willi syndrome

Indexed keywords

GHRELIN; HUMAN GROWTH HORMONE; LEPTIN; NEUROPEPTIDE Y; OXYTOCIN; PEPTIDE HORMONE; PLACEBO;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERPHAGIA; MALE; OBESITY; OPEN STUDY; OXYTOCIN BLOOD LEVEL; PATHOGENESIS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0345602037     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00077-7     Document Type: Article

References (33)

1. P. Burman, M. Ritzén, A.C. Lindgren, Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH, Endocr. Rev. 22 (2001) 787-799.
2. W.B. Zipf, G.G. Berntsson, Characteristics of abnormal food intake patterns in children with Prader-Willi syndrome and study of effects of naloxone, Am. J. Clin. Nutr. 46 (1987) 277-281.
3. A.J. Holland, J. Treasure, P. Coskeran, J. Dallow, Characteristics of the eating disorder in Prader-Willi syndrome: implications for treatment, J. Intell. Disability Res. 39 (1995) 373-381.
4. A.C. Lindgren, B. Barkeling, A. Hägg, M. Ritzén, C. Marcus, S. Rössner, Eating behaviour in Prader-Willi syndrome, normal weight and obese control groups, J. Pediatr. 137 (2000) 50-55.
5. F. Swaab, J.S. Purba, M.A. Hofman, Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons in Prader-Willi syndrome: a study of five cases, J. Clin. Endocrinol. Metab. 80 (1995) 573-579.
6. C. Höybye, A. Hilding, H. Jacobsson, M. Thorén, Growth hormone treatment improves body composition in adults with Prader-Willi syndrome, Clin. Endocrinol. (Oxf.) 58 (2003) 653-661.
7. V.S. Herman-Bonert, D. Prager, S. Melmed, Growth Hormone. GH and Metabolism, The Pituitary, Blackwell Science, Cambridge, MA, 1995, pp. 112-113.
8. M.W. Schwartz, S.C. Woods, D. Porte Jr., R.J. Seeley, D.G. Baskin, Central nervous control of food intake, Nature 404 (2000) 661-671.
9. Y. Zhang, R. Proenca, M. Maffai, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue, Nature 372 (1994) 425-432.
10. M. Kojima, H. Hosoda, Y. Date, M. Nacazato, H. Matsuo, K. Kangawa, Ghrelin is a growth-hormone releasing acytylated peptide from the stomach, Nature 402 (1999) 656-660.
11. A.M. Wren, L.J. Seal, M.A. Cohen, A.E. Brynes, G.S. Frost, K.G. Murphy, W.S. Dhillo, M.A. Ghatei, S.R. Bloom, Ghrelin enhances appetite and increases food intake in humans, J. Clin. Endocrinol. Metab. 86 (2001) 599-602.
12. A. Caixas, C. Bashore, A. Trause, F.X Pi-Sunyer, B. Laferrere, Feeding acutely suppresses ghrelin levels in normal weight human subjects, Obes. Res. 9 (Suppl. 3) (2001) 73S.
13. C. Höybye, A. Hilding, H. Jacobsson, M. Thorén, Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity, J. Clin. Endocrinol. Metab. 87 (2002) 3590-3597.
14. D.E. Cummings, K. Clement, J.Q. Purnell, C. Vaisse, K.E. Foster, R.S. Frayo, M.W. Schwartz, A. Basdevant, D.S. Weigle, Elevated plasma ghrelin levels in Prader-Willi syndrome, Nat. Med. 7 (2002) 643-644.
15. A. DelParigi, M. Tschop, M.L. Heiman, A.D. Salbe, B. Vozarova, S.M. Sell, J.C. Bunt, P.A. Tataranni, High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome, J. Clin. Endocrinol. Metab. 87 (2002) 5461-5464.
16. V.A. Holm, S.B. Cassidy, M.G. Butler, J.M. Hanchett, L.R. Greenswag, B.Y. Whitman, F. Greenberg, Prader-Willi syndrome: consensus diagnostic criteria, Pediatrics 91 (1993) 398-401.
17. A.C. Lindgren, U. Grandell, E.M. Ritzén, M. Anvret, Diagnosis of the Prader-Willi syndrome by proving the absence of methylated PW71 DNA fragment, Acta Paediatr. 85 (1996) 195-198.
18. M. Petersson, A.-L. Hulting, R. Andersson, K. Uvnäs-Moberg, Long-term changes in gastrin, cholecystokinin and insulin in response to oxytocin treatment, Neuroendocrinology 69 (1999) 202-208.
19. S. Stock, L. Granström, L. Backman, A.S. Matthiesen, K. Uvnäs-Moberg, Elevated plasma levels of oxytocin in obese subjects before and after gastric banding, Int. J. Obes. 13 (1989) 213-222.
20. P. Bang, I.E. Wiwall, U. Eriksson, V. Sara, K. Hall, Comparison of acid ethanol extraction and acid gel filtration prior to IGF-1 and IGF-2 radioimmunoassays: improvement of determination in acid ethanol extracts by the use of truncated IGF-1 as radioligand, Acta Endocrinol. (Copenh) 107 (1991) 563-570.
21. A. Hilding, K. Hall, I.L. Wivall-Helleryd, M. Sääf, A.L. Melin, M. Thorén, Serum levels of insulin-like growth factor-1 in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects, J. Clin. Endocrinol. Metab. 84 (1999) 2013-2019.
22. S.F. Leibowitz, N.J. Hammar, K. Chang, Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat, Physiol. Behav. 27 (1981) 1031-1040.
23. B.R. Olsson, M.D. Dutarosky, M.S. Chow, V.J. Hruby, E.M. Stricker, J.G. Verbalis, Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats, Peptides 12 (1991) 113-118.
24. A. Martin, M. State, G.M. Anderson, W.M. Kay, Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report, Biol. Psychiatry 44 (1998) 1349-1352.
25. D.E. Cummings, J.Q. Purnell, R.S. Frayo, K. Schmidova, B.E. Wisse, D.S. Weigle, A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans, Diabetes 50 (2001) 1714-1719.
26. E. Ravussin, M. Tschop, S. Marales, C. Bouchard, M.L. Heiman, Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins, J. Clin. Endocrinol. Metab. 86 (2001) 4547-4551.
27. T. Shiiya, M. Nakazato, M. Mizuta, Y. Date, M.S. Mondal, M. Tanaka, S. Nozoe, H. Hosoda, K. Kangawa, S. Matsukura, Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion, J. Clin. Endocrinol. Metab. 87 (2002) 240-244.
28. M. Tschoep, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity, Diabetes 50 (2001) 707-709.
29. A.M. Haqq, I.S. Farooqi, S. O'Rahilly, D.D. Stadler, R.G. Rosenfeld, K.L. Pratt, S.H. La Franchi, J.Q. Purnell, Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome, J. Clin. Endocrinol. Metab. 88 (2003) 174-178.
30. J.A. Janssen, F.M. van der Toorn, L.J. Hofland, P. van Koetsveld, F. Broglio, E. Ghigo, S.W. Lamberts, A. Jan van der Lely, Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy, Eur. J. Endocrinol. 145 (2001) 711-716.
31. M. Maffei, J. Halaas, E. Ravussin, R.E. Pratley, G.H. Lee, Y. Zhang, H. Fei, S. Kim, R. Lallone, S. Rangnanthan, et al., Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects, Nat. Med. 1 (1995) 1155-1161.
32. T.S. Gray, J.E. Morley, Neuropeptide Y. Anatomical distribution and possible function in mammalian nervous system, Life Sci. 38 (1986) 389-401.
33. S.E. Meyers, A. Davis, B.Y. Withman, J.U. Santiago, M. Landt, Leptin concentrations in PWS before and after growth hormone replacement, Clin. Endocrinol. (Oxf.) 52 (2000) 66-72.